Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
DISASTERS AVERTED — Near Miss Case Studies
SGLT2 Inhibitors for Kidney Disease
TOP STORIES — Diabetes News and Research
Diabetes Prevention: The Key To Reducing End-stage Kidney Disease
Glycemic Control May Reduce the Risk of Parkinson’s Disease
Semglee: Insulin Glargine “Biosimilar” Approved for Diabetes in the US
MOST POPULAR ARTICLES OF THE MONTH
#1 Vitamin D Supplementation Reduces the Risk of T2DM
#2 The Low-Carbohydrate Effect
#3 Predictors of COVID-19 Outcomes in Patients with Diabetes
Letter from the Editor
Melinda Rodriguez, PharmD Candidate 2021, Lake Erie College of Osteopathic Medicine, is attempting to help us understand the concept of Biosimilars. Her drug class of choice to unravel the process is insulin. In her feature this week she looks at the radical changes the FDA has to make to allow the almost, but not quite, duplication of the branded product.
As this trend continues, it will be interesting to see if lower insulin prices will become the norm, or will PBM’s keep these products off formularies so they can get their branded rebates?
*****************************
We can make a difference!
*****************************
Dave Joffe
Editor-in-chief
DISASTERS AVERTED — Near Miss Case Studies
A 56-year old male with type 2 diabetes and stage 3 chronic kidney disease contacted us recently regarding his new prescription for the SGLT2 inhibitor canagliflozin (Invokana)….
TOP STORIES — Diabetes News and Research
Earlier onset of type 2 diabetes equals higher risk of kidney transplant.
A recent population-based cohort study offers more insight into the link between glycemic status and the risk for PD.
A milestone in the push for improved access and affordability of life-saving medications.